MedTrace Logo

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 408

Last updated 2025-12-18

No results posted yet for this study

Summary

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

INCA33890

INCA33890 will be administered at protocol defined dose.

DRUG

bevacizumab

Bevacizumab will be administered at protocol defined dose.

DRUG

FOLFIRI

FOLFIRI will be administered at protocol defined dose.

DRUG

FOLFOX

FOLFOX will be administered at protocol defined dose.

DRUG

Cetuximab

Cetuximab will be administered at protocol defined dose.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-24
Primary Completion
2027-01-13
Completion
2027-01-13
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • France
  • Italy
  • Japan
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05836324 on ClinicalTrials.gov